Adaptive Biotechnologies Corporation (FRA:1HM)

Market Cap	1.98B +74.0%
Revenue (ttm)	235.90M +54.8%
Net Income	-50.68M
EPS	-0.33
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	133
Open	13.47
Previous Close	13.26
Day's Range	13.47 - 13.47
52-Week Range	5.70 - 17.71
Beta	n/a
RSI	44.17
Earnings Date	Feb 5, 2026

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as M...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2009
• Employees: 619
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1HM

Financial Performance

In 2025, Adaptive Biotechnologies's revenue was $276.98 million, an increase of 54.77% compared to the previous year's $178.96 million. Losses were -$59.50 million, -62.69% less than in 2024.

Financial numbers in USD